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Abstract
Objectives: To analyze psychological profiles, pain and oral symptoms in patients with oral 
lichen planus (OLP).
Materials and methods: 300 patients with keratotic OLP (K-OLP; reticular, papular, plaque-like 
subtypes), 300 patients with predominant non-keratotic OLP (nK-OLP; erythematosus atrophic, 
erosive, ulcerative, bullous subtypes) and 300 controls were recruited in 15 universities. The 
number of oral sites involved and oral symptoms were recorded. The Numeric Rating Scale 
(NRS), Total Pain Rating Index (T-PRI), Hamilton Rating Scales for Depression and for Anxiety 
(HAM-D and HAM-A), Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale 
(ESS) were administered.
Results: The OLP patients, especially the nK-OLP, showed higher scores in the NRS, T-PRI, 
HAM-D, HAM-A and PSQI compared with the controls (p-value<.001**). A positive correlation 
between the NRS, T-PRI, HAM-A, HAM-D and PSQI was found with the number of oral 
symptoms and number of oral sites involved. Pain was reported in 67.3 % of nK-OLP and 49.7% 
of K-OLP cases with poor correspondence between the site of lesions and the site of the 
symptoms.
Conclusions: Mood disorders are frequently associated with OLP with an unexpected 
symptomatology correlated with the number of oral symptoms and with the extension of disease 
suggesting a peripheral neuropathy.
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Introduction
Oral lichen planus (OLP) is an immune‐mediated inflammatory chronic disease of the oral 
mucosa, with an unknown etiology (DeAngelis, Cirillo & McCullough, 2019) and a global 
prevalence of 1.01% (González-Moles et al 2020). The association of several psychological 
comorbidities, such as anxiety (A), depression (D) and sleep disturbance (SD) has been reported 
and should be evaluated in the patient's clinical management (Rojo‐Moreno et al, 1998; 
Chaudhary, 2004; Lundqvist et al, 2006; Gavic et al 2014, Adamo et al. 2015; Wiriyakijja et al 
2020). OLP may have different patterns of clinical manifestations which range from keratotic 
manifestations (white reticular, papular and/or plaque-like lesions) to predominantly non-keratotic 
lesions (atrophic, erythematous and/or erosive, ulcerative or bullous lesions) (Alrashdan, Cirillo & 
McCullough, 2016; Carrozzo, et al, 2019). Furthermore, clinical variants can change over time in 
the same patient.
Keratotic OLP (K-OLP) is usually asymptomatic while predominantly non-Keratotic OLP 
(nK-OLP) is associated to oral discomfort, burning sensation and even severe pain (Park, Hurwitz 
& Camp; Woo; 2012; Alberdi-Navarro, Aguirre-Urizar, & Ginestal-Gómez; 2020). Painful lesions 
may affect eating, swallowing and speaking, causing an impaired quality of life in OLP patients 
(Wiriyakijja et al 2020). Moreover, other complex oral symptoms, probably related to changes in 
the surface of the oral mucosa, have been reported (Larsen et al, 2017; Adamo et. al 2017). This 
symptomatology, in association with an unpredictable behavior of the disease and the risk of 
cancer development, could contribute to an impaired psychological well-being, causing emotional 
changes and a worsening of the quality of life of patients, which in time could amplify the 
symptoms of pain (Radwan-Oczko et al 2018; Vilar-Villanueva et al 2019, Wiriyakijja et al 2020).
It is also necessary to consider that pre‐existing mood disorders may affect the perception of 
pain and the ability of the patient to cope with the disease and its symptoms, contributing not only 
to the development but also an exacerbation of the disease (Mohamadi Hasel et al, 2013). 
Until now, a few single center studies have evaluated the prevalence of mood disorders in 
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Wiriyakijja et al 2020; Wiriyakijja et al 2020), analyzing the differences between K-OLP and nK-
OLP, with unclear results (Rojo-Moreno et al 1998), and no evident relationships between 
intensity and quality of pain (Larsen et al 2017). 
Recently, a high prevalence of A, D and SD in a group of patients with K-OLP has been 
identified (Adamo et al 2017; Alberdi-Navarro, Aguirre-Urizar & Ginestal-Gómez 2020). In 
addition, this subset of patients was strongly symptomatic (Adamo et al 2018) with a prevalent 
burning as an oral complaint in addition to mood disorders (Adamo et al 2017).
Therefore, we decided to perform a multicenter case-control study in a large cohort of 
patients with different OLP clinical patterns in order to better evaluate the potential relationships 
between pain, burning sensations and mood disorders in this disease. To the best of our knowledge 
this is the first study which assesses oral symptoms and mood disorders in such a large number of 
patients with OLP.
The primary aim of this study was to analyze the psychological profile (A, D and SD), the 
reported pain and additional intra-oral symptoms in cohorts of patients with K-OLP and nK-OLP, 
comparing the results between the two groups and with those relative to the control group.
The secondary objective of the present study was to analyze the topographic correlation 
between the site of the pain and the location of the OLP lesions and to investigate the correlation 
between the intensity and quality of the pain with the demographic factors, psychological profile, 
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Material and Methods
Study design
This was an observational multicenter case–control study carried out in fifteen Italian Oral 
Medicine outpatients' departments of different Italian Universities (eight northern, three central 
and four southern universities) join with the Italian Society of Oral Pathology and Medicine 
(SIPMO- Società Italiana di Patologia e Medicina Orale). The Oral Medicine department of 
Federico II university of Naples was the chief investigator center and the Ethics Committee of the 
Federico II University of Naples approved the study (reference number: 184/18). All the other 
Oral Medicine departments which participated at the study, had to obtain the ethical approval by 
their local ethics committees. The study was conducted in accordance with the ethical principles of 
the World Medical Association Declaration of Helsinki.
Participants
Overall, the study groups comprised a total of 300 K-OLP patients and 300 nK-OLP patients 
selected for the OLP group, and 300 healthy subjects for the control group.
The participants’ recruitment was conducted between December 2018 and January 2020 and 
was based upon a convenience sampling. All potentially eligible participants in all Oral Medicine 
outpatients’ clinics, were invited to participate at the present study and provided their written 
informed consent.
Recruitment process ended when each department had included a total of twenty patients with 
K-OLP, twenty patients with nK-OLP and twenty healthy control subjects. The patients and 
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gender distribution and the average age; secondly, we recruited the controls to obtain matched 
sample.
Participants of either gender and aged 18 or older were included based upon the following 
inclusion/exclusion criteria. The inclusion criteria for the K-OLP and nK-OLP were: (i) a clinical 
and histopathological confirmation of OLP based upon the modified WHO diagnostic criteria (van 
der Meij & van der Waal, 2003); (ii) patients with exclusive keratotic pattern (presence of white 
reticular, papular and/or plaque-like lesions) of the oral cavity were included in the K-OLP group; 
(iii) patients with a predominant non-keratotic pattern and the occurrence of atrophic, 
erythematous, erosive, ulcerative and /or bullous lesions with or without the presence of keratotic 
lesions were included in the nK-OLP group. 
The exclusion criteria for both the K-OLP and nK-OLP groups were: (i) pregnant or 
breastfeeding women; (ii) evidence of oral epithelial dysplasia; (iii) a suspicion that the oral 
lesions may be related to any drug use or oral restoration; (iv) the presence of any other identified 
oral mucosal disease, autoimmune disease, serious systemic disease or tumor, or a history or 
occurrence of psychiatric illness as defined by the American Psychiatric Association Diagnostic 
and Statistical Manual of Mental Disorders 5 (DSM‐5); (v) a history of alcohol or substance 
abuse; (vi) ongoing treatment with systemic and/or topical corticosteroids or with psychotropic 
drugs; (vii) an inability to understand the questionnaires.
The inclusion criteria for the control group encompassed: (i) patients referred to the same 
University Dental Clinics for routinely dental care during the study period; (ii) the absence of any 
oral mucosal lesions. The exclusion criteria for the healthy controls were: (i) pregnant or 
breastfeeding women; (ii) the presence of any autoimmune disease, serious systemic disease or 
tumor or a history or occurrence of psychiatric illness as defined by the DSM‐5; (iii) a history of 
alcohol or substance abuse; (iv) ongoing treatment with a psychotropic drug; (v) an inability to 
understand the questionnaires.
Sample size calculation
The sample size, namely 300 subjects for each of the three groups, was set by fixing a test 
power of no less than 90% associated with a significance of no more than 5% (software G*Power 
3.1.9.7 by Dusseldorf University). This sample size calculation was performed using the effect 
size estimation from a previous published research study regarding scales of mood disorders and 
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Procedure
All the patients underwent a comprehensive intra- and extra-oral examination carried out by 
two oral medicine experts with a documented experience in the evaluation and treatment of OLP. 
At admission, sociodemographic data such as age, gender, educational level (in years), marital 
status, job status, social habits (smoking and alcohol consumption), oral mucosal disease onset, 
body mass index (BMI), the presence of any systemic diseases and drug consumption were 
recorded for the patients and controls. Participants were given a set of questionnaires evaluating 
the intensity and quality of pain, their psychological status (level of anxiety and depression) and 
quality of sleep. 
The questionnaires comprised:
- the Numeric Rating Scale (NRS) and Total Pain Rating Index (T-PRI) from the Short Form of 
the McGill Pain Questionnaire (SF-MPQ) for the assessment of the oral discomfort, and the 
intensity and quality of pain (Hjermstad et al 2011; Melzack ,1987);
- the Hamilton Rating Scale for Depression (HAM-D) and the Hamilton Rating Scale for Anxiety 
(HAM-A) for the evaluation of depression and anxiety (Hamilton 1958; Hamilton 1960);
- the Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS) for the 
assessment of sleep (Curcio et al; 2013; Vignatelli et al 2003).
All the questionnaires were reviewed for completeness before collection and were administered in 
their Italian versions. The present study was reported in accordance with the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) guidelines for observational 
studies (Appendix) (von Elm et al, 2014).
Outcomes 
The outcomes evaluated for the primary objective of the present study were the presence of 
psychological comorbidities as measured by HAM-A, HAM-D, PSQI, ESS, and the reported pain 
as measured by NRS, T-PRI along with additional intra-oral symptoms, with the aim to detect any 
potential differences between the OLP subgroups and the control group. For the secondary 
objective, we recorded the location of the reported pain in each patient and the location of the 
OLP-lesions in order to investigate the topographic correlation between the site of the pain and the 
location of the OLP lesions. Finally, we looked at the correlation between the intensity and quality 
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sites of OLP lesions involved. To determine associated predictors of psychological profile and 
pain, the clinical type of OLP (K-OLP versus nK-OLP) the number of oral symptoms and the 
number of oral sites were also assessed. In addition, independent predictors of worse pain were 
investigated. Demographic factors (gender, age, education, family status and employment), current 
smoker, alcohol use (at least ≤ 14 units/week) and body mass index, psychological factors 
(anxiety, depression and sleep disturbance) and clinical types of OLP (K-OLP and nK-OLP) were 
considered.
Outcome measures
Measures of oral pain
The Numeric Rating Scale (NRS-11) is a well-validated instrument for the evaluation of pain 
intensity. whose scale ranges from 0 to 10 (0= no oral symptoms and 10=the worst imaginable 
discomfort). Respondents are asked to report pain intensity in the last 24 hours (Hjermstad et al 
2011).
The Total Pain Rating Index (T-PRI) from the short form of the McGill Pain Questionnaire (SF-
MPQ) is a measure of the quality of pain and it is a multidimensional pain questionnaire which 
measures the sensory, affective, and evaluative aspects of the perceived pain. It comprises 15 
items from the original MPQ, each scored from 0 (none) to 3 (severe). The T-PRI score is 
obtained by summing the item scores (range 0-45). There are no established critical cut points for 
the interpretation of the scores, and as for the MPQ, a higher score indicates worse pain (Melzack 
,1987)
Measures of psychological factors
The Hamilton Rating Scale for Anxiety (HAM-A) is a measure of anxiety symptoms and it 
comprises 14 items. Scores can range from 0 to 56. A score <17 indicates mild symptoms, scores 
between 18 and 24 indicate mild-to-moderate severity, and scores >25 indicate moderate- to-
severe anxiety (Hamilton 1958). 
The Hamilton Rating Scale for Depression (HAM-D) is a measure of depression symptoms and it 
comprises 21 items pertaining to the affective field. Scores can range from 0 to 54. A score >7 
indicates impairment. Scores in the 7-17 range indicate mild depression, scores between 18 and 24 
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The Pittsburgh Sleep Quality Index (PSQI) is a standardized questionnaire assessing sleep quality 
and disturbances. This instrument comprises 19 items, generating 7 ‘component’ scores: 
subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, 
use of sleep medication and daytime dysfunction. Each item is scored from 0 to 3, with higher 
scores indicating poorer sleep or more frequent sleep problems. Items are combined to yield the 
seven components (scores ranging from 0 to 3), and the sum of the scores for these seven 
components yields 1 global score ranging from 0 to 21. Global scores above five distinguish poor 
sleepers from good sleepers with high sensitivity (90–99%) and specificity (84–87%) (Curcio et 
al; 2013).                                             The Epworth Sleepiness Scale (ESS) measures subject's 
general level of daytime sleepiness. The instrument comprises 8 items assessing the propensity for 
sleep in eight common situations. Subjects rate their likelihood of dozing in each situation on a 
scale of 0 (would never doze) to 3 (a high chance of dozing). The ESS score is the sum of the 
eight items, ranging from 0 to 24, with a cut‐off value of >10 indicating excessive daytime 
sleepiness (Vignatelli et al 2003) 
Clinical assessement
The participants were categorized into two groups considering the clinical variant of OLP 
(K-OLP versus nK-OLP). The sites of oral mucosa involved by OLP lesions were also recorded. 
In addition, the clinicians analyzed the type and number of oral symptoms reported by the patients 
and the number of oral sites involved for both groups.
The oral symptoms reported were pain (often expressed with a predominant burning 
component, xerostomia, dysgeusia, sialorrhea, subjective halitosis, globus pharyngeus, itching 
sensation, intraoral foreign body sensation, tingling, occlusal dysesthesia, changes in the tongue 
morphology, oral dyskinesia and dysosmia (qualitative alteration or distortion of the perception of 
smell). A point was assigned to the presence of each of these symptoms, with a maximum of 13. 
The oral cavity was divided into nine sites: the maxillary gingiva, the mandibular gingiva, 
the right buccal mucosa, the left buccal mucosa, the upper/lower lips, the ventrum and dorsum of 
the tongue, the floor of the mouth, the hard palate, the soft palate. The upper and lower lips and 
the ventrum and dorsum of the tongue were considered each as one site. A point was assigned to 
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Statistical analysis
The statistical analysis was performed using the SPSS software v. 23. Descriptive statistics, 
including means, standard deviations, medians, and interquartile range (IQR), were used to 
analyze the socio-demographic and clinical characteristics of the three groups. The Pearson Chi 
Square test was used to test the significance differences between the percentages in the three 
groups. Differences associated with p values less than .05 or .01 were considered moderately or 
strongly significant, respectively. The non‐parametric ANOVA procedure by Kruskal‐Wallis was 
employed to test for any differences between the recorded medians of the HAM‐D, HAM‐A, 
PSQI, ESS, NRS and T-PRI in the groups. P‐values <.05 were considered to reflect a statistical 
significance. The Mann‐Whitney U test with the Bonferroni correction was performed among the 
same variables in the three groups in any case in which a significant difference in the former test 
was found. In this analysis, P‐values <.008 were considered to represent a statistical significance. 
The Spearman test was used to analyze the correlation between the number of oral symptoms and 
the number of oral sites in relation to the NRS, T-PRI, HAM-A, HAM-D, PSQI and ESS. 
To identify potential predictors of intensity and quality of pain in K-OLP and in nK-OLP 
patients, multiple linear regression analyses were performed, in each of the two OLP groups, 
considering sociodemographic variables, smoking, alcohol use, BMI and psychological profile. 
Full models, when all the variables were entered simultaneously, were used to evaluate the relative 
contributions of these variables to pain.
In detail, a sequential regression model analysis including predictors, one by one, to obtain 
unadjusted coefficient estimations was performed. Moreover, in a final step, we performed a full 
model analysis considering all predictors, simultaneously, to estimate adjusted coefficients. In all 
steps, we provided standard errors of model coefficients which measure the statistical precision of 
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A total of 900 participants, with no missing data recorded, were finally enrolled in the 
present study: 300 nK-OLP patients, 300 K-OLP patients for the study groups, and 300 healthy 
subjects for the control group. The sociodemographic characteristics of the K-OLP and nK-OLP 
patients and controls are summarized in Table 1. A statistically significant difference was found in 
relation to education and BMI between the patients and controls (p-values < 0.001** and 0.041* 
respectively). In addition, the controls were characterized by a significantly higher percentage of 
employment (155 patients; 51.7%) and a higher percentage of smokers (96 patients; 32%). 
Table 2 shows the frequency of systemic comorbidities and the drugs used by the patients of 
the study groups. Hypertension was the most common associated disease for patients and controls 
and a statistically significant difference between patients and controls was found (p-value < 
0.001**). A statistically significant difference was also found in relation to Beta-Adrenergic 
receptor blocker, Calcium channel blocker, ACE-inhibitor, Antiplatelet and Proton Pump Inhibitor 
use between patients and controls. Beta‐Adrenergic receptor blockers, ACE-inhibitors and Proton 
Pump Inhibitors were the most frequently taken drugs by the K-OLP and nK-OLP patients.
The clinical parameters and the multiple comparison test of the K-OLP and nK-OLP patients 
and controls are summarized in table 3. NRS, T-PRI, HAM-A, HAM-D and PSQI scores showed 
a statistically significant difference between the OLP patients and controls (p-value < 0.001**) but 
not with respect to the ESS (p-value 0.315). In addition, a significant statistical difference in 
relation to the NRS, T-PRI and HAM-D scores (p-value < 0.001**; < 0.001** and < 0.07* 
respectively) between the K-OLP and nK-OLP groups was observed, but this was not the case in 
relation to the HAM-A and PSQI scores.
The score analysis of the psychological profiles of the K-OLP and nK-OLP patients has 
shown that 48.3% (145) of the K-OLP patients and 54% (162) of the nK-OLP patients had A 
(HAM-A >7); 44.7% (134) of the K-OLP patients and 51.3% (154) of nK-OLP patients had D 
(HAM-D > 7) and 49% (147) of the K-OLP patients and 51.7% (156) of the nK-OLP patients had 
SD (PSQI >5). No statistically significant difference was detected between the two groups with 
regard to the scores rates distribution.
Table 4 shows the frequency of the oral symptoms, the oral sites involved by OLP lesions,
the location of symptoms for the K-OLP and nK-OLP groups, and the comparison test of the 
number of oral symptoms reported and the number of oral sites associated with pain/burning 
among the K-OLP and nK-OLP groups. For most of these patients, pain was described as burning 
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pain/burning sensation (p-value < 0.001**) and sialorrhea (p-value: 0.004**), these two symptoms 
being the most frequently reported in nK-OLP. Burning was the most frequent and worst oral 
symptom reported, and present in 58.3% (174) of the K-OLP patients and 71.7% (215) of the nK-
OLP patients. The most frequently affected site involved in relation to the pain/burning was the 
tongue for the K-OLP patients (72.6%) and the buccal mucosa for the nK-OLP patients (90.6%). 
In addition, the K-OLP patients more frequently reported a diffusion of the burning to the entire 
oral mucosa, compared with the nK-OLP patients (15.3% versus 8.7%, p-value: 0.012).
From an analysis of these data, it emerges that the frequency of pain/burning was higher 
than the frequency of the oral sites involved by OLP lesions and that these symptoms were 
reported in sites without any clinical manifestation of the disease in each patient group. Therefore, 
there may be a poor topographic relationship between the location of the OLP lesions and the 
location of pain. In oral sites with a lower frequency of OLP lesions, such as the floor of the 
mouth (15.3% of the K-OLP patients and 22.7% of the nK-OLP patients) and the soft palate 
(15.3% of the K-OLP patients and 20.3% of the nK-OLP patients), the subjective perception of 
pain was found in 58.8% and 73.9% of the K-OLP patients, and 54.1% and 71.7% of the nK-OLP 
patients respectively.
 Other frequent symptoms reported were xerostomia (33.7% of the K-OLP patients and 
34.7% of the nK-OLP patients), dysgeusia (19.3% of the K-OLP patients and 22.0% of the nK-
OLP patients), sialorrhea (10.3% of the K-OLP patients 18.7% of the nK-OLP patients) and 
subjective halitosis (18.3% of the K-OLP and 20.3% of the nK-OLP patients).
Relatively uncommon symptoms reported were globus (13.3% of the K-OLP patients and 
22.0% of the nK-OLP patients), itching (11.4% of the K-OLP patients and 22.0% of the nK-OLP 
patients), a tingling sensation (9.7% of the K-OLP patients and 12.7% of the nK-OLP patients), 
occlusal dysesthesia (7.7% of the K-OLP patients and 12.7% of the nK-OLP patients) and 
dysosmia (6.3% of the K-OLP patients and of the nK-OLP patients).
The most frequent site involved by OLP lesions was the buccal mucosa, considering the 
right and left side for both groups (in 46.3% of the K-OLP patients and 45.8% of the nK-OLP 
patients). There was a statistically significant difference in the location of the lesions on the floor 
of the mouth between the K-OLP and nK-OLP groups (p-value: 0.023*).
Moreover, a statistically significant difference was observed in the number of oral symptoms 
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greater number of oral symptoms, but not in terms of the number of oral sites involved (p-value 
0.412).
Table 5 shows a positive correlation between the total scores of the NRS (pain intensity), T-
PRI (pain quality), HAM-A (anxiety), HAM-D (depression) and PSQI (sleep disturbance) with the 
number of oral symptoms reported and the number of oral sites involved for the K-OLP and nK-
OLP groups.
The results of the simultaneous multiple linear regression analyses for the K-OLP and nK-
OLP groups, predicting the intensity and quality of pain (NRS and T-PRI), are shown in Table 6. 
The model tests the contribution of the demographic variables and confounding factors with pain. 
The first model tests the contributions of the demographic variables and habits to the intensity and 
quality of pain (NRS and T-PRI) which were not found to be statistically significant for either the 
K-OLP or nK-OLP groups. The addition of A (model 2) resulted in a significant increase in the R2 
value for NRS (K-OLP: DR2=8.1%; p-value < 0.001**; nK-OLP: DR2=6.4%; p-value < 0.001**) 
and for T-PRI (K-OLP: DR2=4.3%; p-value 0.003*; nK-OLP: DR2=19.8%; p-value < 0.001**). 
The addition of D (model 3) resulted in a significant increase in the R2 value for NRS (K-OLP: 
DR2=4.6 %; p-value < 0.001**; nK-OLP: DR2=3.5%; p-value 0.001**) and for T-PRI (K-OLP: 
DR2=4.1%; p-value < 0.001**; nK-OLP: DR2=15.9 %; p-value < 0.001**). The addition of SD 
(model 4) resulted in a significant increase in the R2 value for NRS (K-OLP: DR2=9.2 %; p-value 
< 0.001**; nK-OLP: DR2=7.7%; p-value 0.001**) and for T-PRI (K-OLP: DR2=2.9 %; p-value 
0.002**; nK-OLP: DR2=10.6%; p.value < 0.001**).The final full model (model 5) in which all of 
the variables were entered simultaneously could explain 11.5%, 4.6%, 10.4% and 21.2% of the 
variance in the total NRS score (pain intensity) and total T-PRI score (quality of pain), 
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Discussion
The present study provides an evaluation of psychological profile and oral symptoms in a 
large group of patients with different OLP clinical patterns.
The association of psychological factors with OLP and their role with respect to this 
condition continue to be frequently underestimated despite several studies have suggested that 
stress, anxiety, depression, and sleep disturbances could affect and impair the patient’s quality of 
life, and contribute to the onset and exacerbation of the disease (Vallejo et al 2001; Alves et al, 
2015; Adamo et al 2015; Manczyk et al 2019; Vilar-Villanueva et al 2019, Wiriyakijja et al 2020). 
 Similar to these considerations, a recent meta-analysis of Jalenques et al showed a 
prevalence of depression and anxiety in 27% and in 28%, respectively, of patients affected by 
lichen planus (Jalenques et al 2020). Similarly, Wiriyakijia et al found a prevalence of anxiety and 
depression of 39.3% and 20.77 %, respectively, in 260 OLP patients and concluded that anxiety 
was the second most common comorbidity in OLP patients after hypertension (Wiriyakijia et al 
2020). These findings were close with the results of the study from Gavic et al. (Gavic et al, 
2014).
The results of the present research further confirm the higher prevalence of anxiety and 
depression, but also of sleep disturbances, in OLP patients compared with healthy subjects. Until 
now, this is the first case control study examining the prevalence of mood disorders in such a large 
group of patients with OLP. In the OLP patients considered we found anxiety in 51% (307 out of 
600 patients), depression in 48% (291 out of 600) and SD in 50.5 % (303 out of 600). An analysis 
of multiple comparisons revealed that the nK-OLP pattern was associated with a higher frequency 
of depression compared with K-OLP while no differences in the prevalence of anxiety and sleep 
disturbances were found between the two groups. Therefore, the prevalence of mood disorders in 
OLP was definitely higher compared with the results of the previous studies and mood disorders 
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results confirm the higher prevalence of anxiety in OLP compared with other psychological 
factors such as depression, as also previously described (Girardi et al, 2011; Zucoloto et al 2019; 
Liao et al, 2020).
Considering the differences in the clinical variants of OLP, we found a higher prevalence of 
depression in nK-OLP patients compared with K-OLP patients, in contrast with other previous 
studies (Lundqvist et al 2006; Rojo-Moreno et al, 1998; Vallejo et al. 2001; Lundqvist et al 2006) 
that reported a higher prevalence of both psychological comorbidities in erosive OLP.
In this study, a comprehensive analysis of painful oral symptoms was carried out, 
considering that pain is the most important reason encouraging OLP patients to seek treatment 
from a clinician (Lodi et al 2012; Gupta, Ghosh, &amp; Gupta, 2017). In our study, the OLP 
patients reported a great frequency of oral discomfort (64.3%; 389 patients), mostly referred as 
burning sensation, with the nK-OLP patients reporting a higher prevalence and significantly 
greater level of pain compared with the K-OLP patients. Most of these patients reported a long 
duration of continuous pain/burning present daily, worsening with sour or spicy food. It is 
interesting to note that 174 (58.3%) K-OLP patients, a cluster generally asymptomatic, reported 
pain/ burning symptoms diffuse in the entire oral mucosa in 15.3% (45) of cases. However, there 
was a poor topographic relationship between location of the OLP lesions and the reported 
pain/burning, which was also described in sites without OLP lesions in both groups. This seems to 
suggest that in many cases pain is not correlated with the site of lesions. In addition to pain, many 
K-OLP patients presented several complex additional symptoms, some of which have never 
previously been reported, such as occlusal dysesthesia, oral dyskinesia and dysosmia (qualitative 
alteration or distortion of the perception of smell).
The median number of oral symptoms was higher for the nK-OLP patients while no 
differences in terms of the extension of the disease (number of sites involved by OLP lesions) was 
found between the two groups. The correlation analysis revealed that anxiety, depression, sleep 
disturbances and the intensity and quality of pain/burning were positively correlated with the 
number of oral symptoms and with the number of oral sites involved. Therefore, there was an 
association between a higher number of symptoms and a higher number of sites involved by OLP 
lesions and higher scores in anxiety, depression and sleep disturbances, also with a greater 
subjective perception in the intensity and quality of pain. However, the quality and intensity of 
pain was poorly correlated with mood disorders suggesting that the perception of pain seems to be 
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analysis of the last model of the hierarchical regression (model 5), suggests that the 
sociodemographic variables, habits, anxiety, depression and sleep disturbances could explain only 
11.5% and 8.9 % of the variance in pain intensity for the K-OLP and nK-OLP patients 
respectively, and only 10.4% and 21.2% of the variance in quality of pain for the K-OLP and nK-
OLP patients, respectively. These results may indicate that pain and mood are processed 
somewhat independently in the central nervous system, as suggested in imaging studies (Lee, 
Nassikas, &Clauw,2011; Martucci, & Mackey,2018).
These findings are relatively new and in contrast with previous studies where OLP patients 
with anxiety and depression reported a higher intensity of oral pain compared with patients with a 
normal psychological status, suggesting that mood disorders may amplify the perception of the 
pain (Adamo et al 2015; Wiriyakijja et al 2020), or with the study of Liao et al. where the anxiety 
was considered as a starting point of the disease possibly occurring prior to the  OLP onset and 
modifying the subjective perception of the patients (Liao et al 2019). However, we cannot exclude 
the possibility that in a long-standing disease, the simultaneous presence of untreated mood 
disorders and the stress associated with the potentially malignant evolution of the disease could 
contribute to an amplification of the pain perception. (Mohamadi et al, 2013).
In previous studies, we identified a subset of patients with K-OLP who were strongly 
symptomatic with a condition resembling that of burning mouth syndrome and were successfully 
treated with antidepressants (Adamo et al 2015; Adamo et al 2017).  Therefore, we concluded that 
some OLP patients may simultaneously present with another disease (Adamo et al 2018). 
However, from the results of the current study it is not possible to exclude the hypothesis of a 
common etiopathogenesis which involves an imbalance in the central and peripheral nervous 
systems.
The central nervous system and the immunological processes are strictly and bidirectionally 
interconnected through neurotransmitters, hormones and cytokines, as demonstrated by 
psychoneuroimmunology (Kusnecov, King, &amp; Husband, 1989). Recent studies have 
suggested that significant immune disturbances in the periphery may concomitantly influence the 
immune state of the brain, which in turn could modify the immune modulation peripheral 
pathways, contributing to the susceptibility of the subject to autoimmune disorders, particularly in 
genetically predisposed individuals (Theofilopoulos, Kono, &amp; Baccala, 2017; Dantzer, 2018).
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increase in local pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), 
interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) and 
interleukin 17 (IL-17), released by the endothelial cells, macrophages and keratinocytes and 
contributing to the recruitment of activated T-lymphocytes (Capuron, L., & Miller, A. H. 2011; Lu 
et al 2015; Wei et al 2018, Carvalho et al 2019, Solimani et al 2019). The T- lymphocytes and pro-
inflammatory cytokine in the oral submucosa have a critical role in the pathogenesis of OLP, and 
in turn may contribute to damage the unmyelinated nerve C small fibers causing an increase in 
pain perception (Magrinelli et al 2015; Duksal et al 2016), in a similar way in which these 
molecules may participate in mutagenic processes leading to the transformation of normal cells 
into cancer cells (Anand, Sarode, & Sarode, 2016; Mravec, Tibensky, & Horvathova, 2020).
In addition, these pro-inflammatory cytokines can access the brain and could negatively 
modulate the descending pain systems (Shubayev et al 2010). In this context, the simultaneous 
presence of mood disorders could additionally contribute to a worsening of this autoimmune 
disease (Liu, & Tang, 2018) through the suppression of the protective immunity, exacerbating the 
chronic inflammation and causing a further increase in the pro-inflammatory cytokines of the 
brain, such as IL-1, IL-6 and IL-10. In turn, this could aggravate the pain perception over the time 
through the activation of the hypothalamic- pituitary-adrenal (HPA) axis and the sympathetic-
adrenal axis induced by the neuroendocrine mediators (Ratnayake et al 2013; Kappelmann et al, 
2020). Furthermore, mood disorders seem to be associated with neuronal activation in some brain 
areas, such as the amygdalae and anterior insula, implicated in processing the 
motivational‐affective /integrative dimension of pain (Giesecke et al 2015; Namkung, Kim, & 
Sawa, 2018).
With a bidirectional relationship, the deficiencies in the activity of the endocrine system may 
contribute to the incidence of immunological diseases (Trombetta, Meroni, Cutolo; 2017). Indeed, 
the increase of certain pro-inflammatory hormones, such as cortisol, prolactin and the estrogens, 
may cause the activation of the local proliferation and distribution of inflammatory cells, and 
subsequently the production of pro-inflammatory cytokines (Cutolo, & Straub, 2009; Girardi et al 
2011). Moreover, these hormonal changes may appear before the symptomatic phase of many 
autoimmune diseases, and therefore it is not possible to exclude the possibility that the first step 
could be an alteration of the HPA axis, which may promote the loss of immunological tolerance 
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Therefore, the results of the present study seem to suggest that the subjective perception of 
pain in some patients can be potentially due to a peripheral and/or central neuropathy, particularly 
in those patients with many sites involved by OLP lesions, independently of the mood disorders, 
which, if present, over time could further amplify the pain.
In the management of OLP it is crucial to assess for the presence of mood disorders and pain 
using validated tools. Scales such as the NRS or Visual Analogic Scale (VAS), which evaluate 
only pain intensity, might not be sufficient to reflect the real impact of the symptoms in the 
patient’s life. Therefore, clinicians should analyze not only the intensity of pain but also the 
psychological profile of their patients. They should consider the clinical subtypes of the OLP 
lesions, the extension of the disease in terms of the oral sites involved, the characteristics of the 
symptomatology of the pain including  its quality and its location,  the topographic relationship 
existing between the lesions and the symptoms, the frequency, duration and modifying factors of 
the oral discomfort as well as the additional oral symptoms in order to better understand the 
characteristics of the patients and plan an adequate treatment.
Until now, in the management of OLP, clinicians have assessed the disease activity based 
only upon the clinical oral presentation of the disease (Escudier, et al 2007; Carrozzo et al, 2019). 
However, the results of this study suggest that patients with OLP show a complex 
symptomatology without a perfect correspondence between the clinical presentation and the 
experience and perception of the symptoms. Therefore, in symptomatic OLP patients for whom 
there is no topographic relationship between the location of the pain and the location of the OLP 
lesions, clinicians should consider a different pharmacological treatment, taking into account also 
the psychological profile of the patient. Currently, no curative treatment has been determined and 
therefore the primary management goal must be to relieve the symptoms of pain (Thongprasom, 
Carrozzo, Furness, & Lodi, 2011). However, if anxiety, depression and sleep disturbances are 
identified, the clinicians must take responsibility for requesting the assistance of other appropriate 
specialists, possibly in a multidisciplinary setting, in order to plan a suitable and comprehensive 
treatment for these patients.
Limitations
The study has several limitations. The primary limitation is the absence of any evaluation of 
the disease activity in accordance with the clinical disease severity score system available in 
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(Zucoloto et al, 2019), where the severity of the clinical signs of OLP was found not to be a 
predictor of mood disorders and pain. In addition, we did not analyze the differences in age, sex 
and psychological profile between the OLP patients with different clinical patterns. Similarly, we 
did not evaluate the differences between the symptom profiles and the scores of anxiety, 
depression and sleep disturbances because it is plausible that the different symptom profiles might 
be associated with different psychological imbalances and their consequences.
Secondly, the results of the study might be considered exploratory and should be interpreted 
carefully, taking into account the cross-sectional design of the study and the fact that the analysis 
was made in tertiary referral Oral Medicine Units, with the presence of confounding factors due to 
the heterogeneity of the case-control study, particularly in multicenter settings.
Finally, it is not possible to establish a cause-effect relationship between pain and mood due 
the nature of the study design.
Conclusions
This study has confirmed the higher prevalence of anxiety, depression and sleep 
disturbances in OLP, with nK-OLP patients presenting a higher prevalence of depression 
symptoms and a significantly greater level of pain compared with K-OLP patients. In addition, 
patients with OLP, particularly nK-OLP patients, exhibit various and complex additional oral 
symptoms, frequently undetected.
This unexpected and subjective symptomatology in OLP patients seems to be strongly 
correlated with the number of additional oral symptoms reported and with the extension of the 
disease in terms of the number of oral sites involved by OLP lesions, and poorly with the 
psychological profile, suggesting a peripheral and central neuropathy in which mood and pain are 
interconnected but processed somewhat independently in the central nervous system.
A multidisciplinary setting is strongly advised for a proper management of patients with 
OLP in which clinicians of different medical specialties should not only focus on the treatment of 
the visible clinical signs of OLP alone but should screen patients carefully, including undertaking 
a comprehensive analysis of the psychological profile and oral symptoms.
They should use validated tools to screen mood disorders and to examine the topographic 
relationship between the symptoms of pain, the lesions and the extension of the disease in order to 
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conventional therapies. Further studies are required to confirm our results and to evaluate the 
causal relationships among these variables and the starting points.
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Table 1.  Socio-demographic profile, body mass index, disease onset, and risk factors in the 300 K-
OLP, 300nK-OLP patients and 300 controls. 












Age (in years) Mean ± SD Mean ± SD Mean ± SD 0.686 
65.2 ± 12.2 64.6 ± 12.6 64.2 ± 16.9 
Education (in years) Mean ± SD Mean ± SD Mean ± SD <0.001** 






Frequency (%) Frequency (%) Frequency (%)  




























Body Mass Index  Mean ± SD Mean ± SD Mean ± SD 0.041* 
24.9 ± 3.9 25.0 ± 4.0 24.3 ± 3.6 
Disease onset (years) Mean ± SD Mean ± SD Mean ± SD 0.020* 
4.5±2.3 4.3±2.7 NA 
Risk factors    P-value 

















































- Yes ( ≤ 14 
units/week) 
- Not 



















IQR is the interquartile range.  The significance difference between medians was measured by the Kruskal-Wallis test. * 
Significant 0.01 < p ≤ 0.05, ** Significant p ≤ 0.01. 
 The Significance difference between the percentages was measured by the Pearson Chi Square test. * Significant 0.01 < p 
≤ 0.05, ** Significant p ≤ 0.01. 
Abbreviations: K-OLP: keratotic oral lichen planus; nK-OLP: non-keratotic oral lichen planus; NRS: numeric rating scale; T-
PRI: total pain rating index; HAM-A: Hamilton rating scale for anxiety; HAM-D: Hamilton rating scale for depression; PSQI: 
Pittsburgh sleep quality index; ESS: Epworth sleepiness scale. 
  
 
This article is protected by copyright. All rights reserved 
Table 2. Frequency of systemic diseases and drug consumption in the 300 K-OLP and 300 










Essential Hypertension 32.7% 48.0% 26.0% <0.001** 
Hypercholesterolemia 22.3% 23.0% 16.7% 0.109 
Previous myocardial infarction 2.0% 2.3% 2.7% 0.864 
Diabetes 8.3% 9.3% 7.0% 0.762 
Asthma 2.3% 5.7% 2.3% 0.035* 
Gastro-oesophageal reflux disease 15.3% 21.3% 9.0% <0.001** 
Hepatitis B 1.3% 0.7% 0.0 0.134 
Hepatitis C 3.3% 3.3% 1.3% 0.214 
Endocrine disease 3.7% 5.3% 2.0% 0.094 
Hypothyroidism 11.3% 10.7% 7.0% 0.154 
Hyperthyroidism 1.7% 3.7% 1.3% 0.111 
Benign prostatic hypertrophy 7.0% 6.0% 2.75% 0.044* 
Previous malignant disease 8.0% 8.0% 5.3% 0.341 
Drug Consumption   
Beta‐Adrenergic receptor blockers 15.7% 19.3% 11.7% 0.001** 
Angiotensin II receptor blockers 8.0% 8.3% 5.7% 0.394 
Diuretics 8.0% 8.3% 8.0% 0.985 
Calcium Channel blockers 4.7% 9.3% 3.7% 0.006** 
ACE-inhibitors 9.3% 19.7% 10.3% <0.001** 
Simvastatin 14.3% 19.3% 13.7% 0.115 
Metformin 8.0% 6.7% 5.3% 0.424 
Insulin 2.7% 2.7% 2.0% 0.830 
Antiplatelets 11.7% 16.0% 8.0% 0.010** 
Blood thinner 5.0% 4.7% 2.0% 0.114 
Levothyroxine sodium 12% 12% 6.3% 0.029* 
Proton pump inhibitors 14.0% 19.7% 11.7% <0.001* 
 
The significance difference between percentages was measured by the Pearson Chi Square test.  * Significant 0.01 < p ≤ 









Abbreviations: K-OLP: keratotic oral lichen planus; nK-OLP: non-keratotic oral lichen planus. 
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Table 3:  Clinical parameters and multiple comparison test of the NRS, T‐PRI, HAM‐A, HAM‐D, PSQI 




K-OLP nK-OLP Controls  
P.value Median; IQR Median; IQR Median; IQR 
NRS 2.0; [0 – 5] 4.0; [0.3 – 6] 0.0; [0 – 0] <0.001** 
T-PRI 2.0; [0 – 5] 3.0; [1 – 7] 0.0; [0 – 0] <0.001** 
HAM-A 7.0; [3 – 12] 8.0; [4 – 15] 5.0; [1 – 10] <0.001** 
HAM-D 6.0; [3 – 12] 8.0; [4 – 13] 5.0; [2 – 9] <0.001** 
PSQI 5.0; [3 – 8]  6.0; [4 – 9]  5.0; [3 – 7]  <0.001** 
ESS 4.5.0; [2 – 8]  5.0; [2 – 8]  5.0; [3 – 8]  0.315 
Multiple comparison test 
  K-OLP nK-OLP 
NRS K-OLP ------  
nK-OLP <0.001* ------ 
Controls <0.001* <0.001* 
T-PRI K-OLP -----  
nK-OLP <0.001* ------ 
Controls <0.001* <0.001* 
HAM-A K-OLP ------  
nK-OLP 0.009 ------ 
Controls <0.001* <0.001* 
HAM-D K-OLP ------  
nK-OLP 0.007* ------ 
Controls <0.001* <0.001* 
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IQR is the interquartile range.  The significance difference between medians was measured by the Kruskal-Wallis test.  
* Significant 0.01 < p ≤ 0.05, ** Significant p ≤ 0.01. 
Multiple comparison test using the Mann-Whitney U test with the Bonferroni correction.  
*Test is significant with a p-value<0.008 
Abbreviations: K-OLP: keratotic oral lichen planus; nK-OLP: non-keratotic oral lichen planus; NRS: numeric rating scale; T-
PRI: total pain rating index; HAM-A: Hamilton rating scale for anxiety; HAM-D: Hamilton rating scale for depression; PSQI: 
Pittsburgh sleep quality index; ESS: Epworth sleepiness scale. 
 
  
nK-OLP 0.107 ----- 
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Table 4.  Frequency of oral symptoms, oral sites involved and location of burning in the 300 K-OLP 
and  300 nK-OLP patients and comparison test of the number of oral symptoms reported and the 
number of oral sites involved. 
 
 
Oral symptoms K-OLP Frequency (%) nK-OLP Frequency (%) P-value 





Pain/Burning localized in all sites 15.3% 8.7% 0.012*
 
Xerostomia 33.7% 34.7% 0.819 
Dysgeusia 19.3% 22.0% 0.420 
Sialorrhea 10.3% 18.7% 0.004** 
Subjective Halitosis 18.3% 20.3% 0.535 
Globus pharyngeus 13.3% 17.0% 0.211 
Itching 11.4% 12.7% 0.637 
Intraoral Foreign Body Sensation 11.7% 12.7% 0.708 
Tingling sensation 9.7% 12.7% 0.243 
Occlusal Dysesthesia 7.7% 9.0% 0.555 
Change in tongue morphology 0.7% 0.7% 1.000 
Oral dyskinesia 2.3% 2.7% 0.794 
Dysosmia 6.3% 6.3% 1.000 
Oral sites involved by OLP  K-OLP Frequency (%) nK-OLP Frequency (%) P-value 
Upper Gingiva  21.3% 19.6% 0.407 
Lower Gingiva 21.3% 19.6% 0.407 
Lips 24.0% 29.3% 0.140 
Right Buccal mucosa 23.1% 23% 0.900 
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Tongue  39.7% 41.3% 0.678 
Floor of the Mouth 15.3% 22.7% 0.023* 
Hard Palate 25.3% 30.0% 0.201 
Soft Palate 15.3% 20.3% 0.101 
 
 The significance difference between the percentages was measured by the Pearson Chi Square test.  
 * Significant 0.01 < p ≤ 0.05, ** Significant p ≤ 0.01. 
The significance difference between the medians was measured by the Mann-Whitney U test. 
* Significant 0.01 < p ≤ 0.05, ** Significant p ≤ 0.01. 
 
Abbreviations: K-OLP: keratotic oral lichen planus; nK-OLP: non-keratotic oral lichen planus 
Location of Pain/Burning  K-OLP Frequency (%) nK-OLP Frequency (%) P-value 
Upper Gingivae  40% 43% 
0.001** 
Lower Gingivae 33.9% 42.9% 
0.001** 
Lips 63.6% 83.3% 
0.006** 
Right Buccal mucosa 37% 45.3% 
<0.001** 
Left Buccal mucosa 36.5% 45% 
<0.001** 
Tongue  72.6% 87.4% 
0.004** 
Floor of the Mouth 58.8% 73.9% 
0.098 
Hard Palate 63.3% 81.6% 
0.009** 
Soft Palate 54.1% 71.7% 
0.063 
   
 
Comparison test 
 K-OLP nK-OLP  
Median; IQR Median; IQR P.value 
N° oral symptoms 1.0; [1 – 3] 2.0; [1 – 3] 0.006** 
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Tab 5. Correlation analysis between the number of oral symptoms reported, the number of oral 


















































The significance correlations were measured by the Spearman correlation test. * Significant 0.01 < p ≤ 0.05, ** Significant p 
≤ 0.01. 
Abbreviations: K-OLP: keratotic oral lichen planus; nK-OLP: non-keratotic oral lichen planus; HAM-A: Hamilton rating scale 













This article is protected by copyright. All rights reserved 
Tab 6 Multiple linear regression analysis predicting pain in the 300 K-OLP and 300 nK-OLP patients. 
NRS K-OLP Model 1 Model 2 Model 3 Model 4 Model 5 





























































































  0.09 
(0.02) 





    0.06 
(0.01) 
<0.001**   -0.01 
(0.03) 
0.7471 
Quality of sleep 
(PSQI) 





R2 (%) 0.0 0.850 8.1 <0.001** 4.6 0.002** 9.2 <0.001** 11.5 <0.001** 
R2change (%)   8.1 <0.001** 4.6 <0.001** 9.2 <0.001** 11.5 <0.001** 
NRS   nK-OLP Model 1 Model 2 Model 3 Model 4 Model 5 





















































0.786 -0.02  
(0.03) 






































  0.10 
(0.02) 
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Depression 
(HAM-D) 
    0.08 
(0.02) 
0.001**   -0.02 
(0.02) 
0.503 
Quality of sleep 
(PSQI) 





R2 (%) 1.5 0.08 7.9 <0.001** 5.0 0.002** 9.2 <0.001** 10.4 <0.001** 
R2change (%)   6.4 <0.001** 3.5 0.001** 7.7 <0.001** 8.9 <0.001** 
T-PRI K-OLP Model 1 Model 2 Model 3 Model 4 Model 5 
 Beta (SE) P-value Beta (SE) P-value Beta 
(SE) 





















































0.934 -0.02  
(0.04) 






































  0.09 
(0.02) 





    0.08 
(0.02) 
<0.001**   0.04 
(0.04) 
0.319 
Quality of sleep 
(PSQI) 





R2 (%) 0.0 0.381 4.3 0.003** 4.1 0.004** 2.9 0.019* 4.6 0.004** 
R2change (%)   4.3 <0.001** 4.1 <0.001** 2.9 0.002** 4.6 <0.001** 
T-PRI nK-OLP Model 1 Model 2 Model 3 Model 4 Model 5 
 Beta (SE) P-value Beta (SE) P-value Beta 
(SE) 
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  0.27 
(0.03) 





    0.26 
(0.03) 
<0.001**   0.07 
(0.05) 
0.149 
Quality of sleep 
(PSQI) 





R2 (%) 1.8 0.056 21.6 <0.001** 17.7 <0.001** 12.4 <0.001** 23.0 <0.001** 
R2change (%)   19.8 <0.001** 15.9 <0.001** 10.6 <0.001** 21.2 <0.001** 
 
SE are the standard errors of the beta estimates. The p-values were obtained from the hypothesis test on regression 
coefficients. 
*Moderately significant .01 < p-value ≤ .05.**Strongly significant p-value≤ .01. 
 
Abbreviations: K-OLP: keratotic oral lichen planus; nK-OLP: non-keratotic oral lichen planus; NRS, Numeric Pain Intensity 
Scale; T-PRI, Total Pain Rating Index ; HAM-A: Hamilton  rating scale for anxiety; HAM-D: Hamilton  rating scale for 
depression; PSQI: Pittsburgh sleep quality index.  
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